ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ollivier-Hourmand Isabelle, Repesse Yohann, Nahon Pierre, Chaffaut Cendrine, Dao Thông, Nguyen Thi Thu Nga, Marcellin Patrick, Roulot Dominique, De Ledinghen Victor, Pol Stanislas, Guyader Dominique, Archambeaud Isabelle, Zoulim Fabien, Oberti Frédéric, Tran Albert, Bronowicki Jean-Pierre, D'Alteroche Louis, Ouzan Denis, Peron Jean-Marie, Zarski Jean-Pierre, Bourliere Marc, Larrey Dominique, Louvet Alexandre, Cales Paul, Abergel Armand, Mathurin Philippe, Mallat Ariane, Blanc Jean-Frederic, Nguyen-Khac Eric, Riachi Ghassan, Alric Laurent, Serfaty Lawrence, Antonini Teresa, Moreno Christophe, Attali Pierre, Thabut Dominique, Pilette Christophe, Grange Jean-Didier, Silvain Christine, Carbonell Nicolas, Bernard-Chabert Brigitte, Goria Odile, Wartelle Claire, Moirand Romain, Christidis Christos, Perlemuter Gabriel, Ozenne Violaine, Henrion Jean, Hillaire Sophie, Di Martino Vincent, Amiot Xavier, Sutton Angela, Barget Nathalie, Chevret Sylvie, Ganne-Carrie Nathalie, ANRS CO12 CIRVIR, CIRRAL groups
Аннотация
METHODS: We used two prospective cohorts of Child-Pugh A cirrhosis due to either alcohol or viral hepatitis. Primary end point was the cumulated incidence of 'Decompensation' at 3 years, defined as the occurrence of ascites , hydrothorax, encephalopathy, gastrointestinal bleeding related to portal hypertension, or bilirubin >45 μmol/L. Secondary end points were the cumulated incidences of (1) 'Disease Progression' including a « decompensation» or « the occurrence of one or more parameters » among: prothrombin time (PT) <45%, albumin <28 g/L, Child-Pugh worsening (B or C vs A or B, C vs B), hepatorenal syndrome, and hepato-pulmonary syndrome, (2) other events such as non-malignant portal vein thrombosis (nmPVT), and (3) overall survival.
RESULTS: Patients (n = 1789; 59.9% Non-O group; 40.1% group O) were followed during a median of 65.4 months. At 3 years cumulated incidence of Decompensation was 8.3% in Non-O group and 7.2% in group O (P = .27). Cumulated incidence of Disease Progression was 20.7% in Non-O group and 18.9% in group O (P = .26). Cumulated incidence of nmPVT was 2.7% in Non-O group and 2.8% in group O (P = .05). At 3 years overall survival was 92.4% in Non-O group and 93.4% in group O (P = 1).
CONCLUSION: Non-O group does not influence disease outcome in Child-Pugh A cirrhotic patients. Clinicals trial number NCT03342170.